Ball Corporation is one of the world’s leading suppliers of metal packaging to the beverage, food, personal care and household products industries. The company delivered adjusted earnings of 50 cents per share in first-quarter 2018. Earnings came ahead of the Zacks Consensus Estimate of 45 cents.
Revenue: Ball Corporation beat revenues in the first quarter. The company posted revenues of $2.785 billion, which surpassed the Zacks Consensus Estimate for revenues of $2.603 billion.
Outlook: Ball Corporation reaffirmed its financial goals for 2018. The company expects its free cash flow will be around $900 million and capital spending will be at least $600 million. Notably, Ball Corporation reaffirms that its comparable EBITDA will be $2 billion and free cash flow will be in excess of $1 billion in 2019.
Estimate Trend & Surprise History: You should note that the earnings estimate revisions for Ball Corporation have remained stable prior to the earnings release. The Zacks Consensus Estimate currently stands at 45 cents for the first quarter.
As regards earnings surprise, Ball Corporation has outpaced the Zacks Consensus Estimate in two of the past four quarters, with an average beat of 2.51%.
Zacks Rank: Currently Ball Corporation has a Zacks Rank #4 (Sell). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Market Reaction: Ball Corporation’s shares remained flat in pre-market trading following the release, at the time of this write-up.
Check back later for our full write up on this Ball Corporation earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Image: Bigstock
Ball Corporation (BLL) Beats Q1 Earnings & Revenue Estimates
Ball Corporation is one of the world’s leading suppliers of metal packaging to the beverage, food, personal care and household products industries. The company delivered adjusted earnings of 50 cents per share in first-quarter 2018. Earnings came ahead of the Zacks Consensus Estimate of 45 cents.
Revenue: Ball Corporation beat revenues in the first quarter. The company posted revenues of $2.785 billion, which surpassed the Zacks Consensus Estimate for revenues of $2.603 billion.
Outlook: Ball Corporation reaffirmed its financial goals for 2018. The company expects its free cash flow will be around $900 million and capital spending will be at least $600 million. Notably, Ball Corporation reaffirms that its comparable EBITDA will be $2 billion and free cash flow will be in excess of $1 billion in 2019.
Estimate Trend & Surprise History: You should note that the earnings estimate revisions for Ball Corporation have remained stable prior to the earnings release. The Zacks Consensus Estimate currently stands at 45 cents for the first quarter.
As regards earnings surprise, Ball Corporation has outpaced the Zacks Consensus Estimate in two of the past four quarters, with an average beat of 2.51%.
Ball Corporation Price and EPS Surprise
Ball Corporation Price and EPS Surprise | Ball Corporation Quote
Zacks Rank: Currently Ball Corporation has a Zacks Rank #4 (Sell). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Market Reaction: Ball Corporation’s shares remained flat in pre-market trading following the release, at the time of this write-up.
Check back later for our full write up on this Ball Corporation earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>